Elicio Therapeutics shares slide after Phase 2 PDAC data
- Elicio Therapeutics (NASDAQ:ELTX) reported that its Phase 2 AMPLIFY-7P study of ELI-002 7P for pancreatic cancer did not meet its primary disease-free survival endpoint.
- Following the news, the company's share price closed at $5.29 per share.
- Management plans to launch a refined Phase 3 trial focused on R0 resected patients, contingent on securing additional financing.
Elicio Therapeutics (NASDAQ:ELTX) announced results from its randomized Phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in patients with mKRAS-driven pancreatic ductal adenocarcinoma.
The study did not achieve its primary endpoint for disease-free survival in the overall intent-to-treat patient population.
The company identified a baseline imbalance where the treatment arm included 19% of patients with R1 resection status compared to 10% in the observation arm.
In a post-hoc analysis of the R0 completely resected population, the therapy showed a hazard ratio of 0.65 with a p-value of 0.048.
The company stated it expects existing cash and cash equivalents to fund operations into the fourth quarter of 2026.
Elicio continues to evaluate multiple strategic financing and partnership opportunities to support its planned Phase 3 development program.
